Transferrin-labeled magnetolipsomes: preparation and magnetic resonance imaging in vitro

doi:10.3969/j.issn.2095-4344.2017.06.018

Abstract

Abstract:

BACKGROUND: Transferrin (Tf) is one suitable ligand to be conjugated to drug delivery systems to achieve site-specific targeting and desired therapeutic effect, due to its specific binding to transferrin receptors (TfR), and high expression on the surface of tumor cells. Contrast agents are also modified with Tf to achieve specific tumor imaging.
OBJECTIVE: To prepare Tf-labeled magnetoliposomes (MLs), and characterize their utility as TfR targeted MR specific contrast agent in vitro.
METHODS: MLs and Tf-MLs were prepared by lipid film hydration method and covalent coupling method, respectively. Tf-MLs were characterized by their mean size, zeta potential, polyindex, r2 relaxivity, Tf-binding efficacy and cytotoxicity. In vitro MRI contrasting properties of the suspended nanoparticles incubated with HepG2 cells were determined.
RESULTS AND CONCLUSION: The mean diameter, polydisperisity index, zeta potential and r2 relexivity of Tf-ML were 95.1 nm, 0.21, -1.25 mv and 94.62 mmol-1/s, respectively. The coupling efficiency was calculated and the values obtained were 59.4 μg Tf/μmol phospholipid corresponding to about 27 molecules of Tf-MLs. After a 2-hour incubation with rhodamine-labeled Tf-MLs, rhodamine fluorescence was detected intensively in the plasma membrane and the cytoplasm of the TfR-overexpressing HepG2 cells. In contrast, Tf-ML showed little binding in MCF-7 cells that had low TfR level. HepG2 cells incubated with Tf-ML showed much higher intracellualar iron density than incubated with non-targeted MLs. In vitro MR T2WI of cells demonstrated the centrifuge tube containing HepG2 cells incubated with Tf-MLs produced a lower visible signal intensity than that treated with non-targeted MLs. Tf-MLs showed their potentials such as high r2 relaxivity, specific binding ability characteristics. These results suggest the availability of Tf-MLs to serve as a targeted contrast agent.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Liposomes, Receptors, Transferrin, Nanoparticles, Magnetic Resonance Imaging, Tissue Engineering

CLC Number:

R318

Chen Wei-cui, Liu Shu-yi, Lin Ai-hua, Liu Xian. Transferrin-labeled magnetolipsomes: preparation and magnetic resonance imaging in vitro[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(6): 923-927.

Figures/Tables 5

References

[1]Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today. 2005;10(4):267-273.

[2]Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291-317.

[3]Soenen SJ, Vande Velde G, Ketkar-Atre A, et al. Magnetoliposomes as magnetic resonance imaging contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(2):197-211.

[4]陈鸿琪.蛋白质定量分析的进展[J].理化检验:化学分册. 2000, 36(7):33-36.

[5]Kobayashi T, Ishida T, Okada Y, et al. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007;329(1-2):94-102.

[6]Guo Y, Wang L, Lv P, et al. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett. 2015;9(3):1065-1072.

[7]Szwed M, Wrona D, Kania KD, et al. Doxorubicin-transferrin conjugate triggers pro-oxidative disorders in solid tumor cells. Toxicol In Vitro. 2016;31:60-71.

[8]Salvatore A, Montis C, Berti D, et al. Multifunctional Magnetoliposomes for Sequential Controlled Release. ACS Nano. 2016;10(8):7749-7760.

[9]Hodenius M, Würth C, Jayapaul J, et al. Fluorescent magnetoliposomes as a platform technology for functional and molecular MR and optical imaging. Contrast Media Mol Imaging. 2012;7(1):59-67.

[10]Rodrigues AR, Gomes IT, Almeida BG, et al. Magnetic liposomes based on nickel ferrite nanoparticles for biomedical applications.Phys Chem Chem Phys. 2015;17(27):18011-18021.

[11]Martins MB, Corvo ML, Marcelino P, et al. New long circulating magnetoliposomes as contrast agents for detection of ischemia-reperfusion injuries by MRI. Nanomedicine. 2014; 10(1):207-214.

[12]Moore A, Josephson L, Bhorade RM, et al. Human transferrin receptor gene as a marker gene for MR imaging. Radiology. 2001;221(1):244-250.

[13]Yang R, Tang Q, Miao F, et al. Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice. Int J Nanomedicine. 2015;10:7345-7358.

[14]Ketkar-Atre A, Struys T, Dresselaers T, et al. In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes. Biomaterials. 2014;35(3):1015-1024.

[15]Kozlowska D, Foran P, MacMahon P, et al. Molecular and magnetic resonance imaging: The value of immunoliposomes. Adv Drug Deliv Rev. 2009;61(15):1402-1411.

[16]Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 2011;150(1):2-22.

[17]Koshkaryev A, Sawant R, Deshpande M, et al. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev. 2013;65(1):24-35.

[18]Miller AD. Lipid-based nanoparticles in cancer diagnosis and therapy. J Drug Deliv. 2013;2013:165981.

[19]Vithanarachchi SM, Allen MJ. Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging. Curr Mol Imaging. 2012;1(1):12-25.

[20]Lei Y, Hamada Y, Li J, et al. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. J Control Release. 2016;232:131-142.

[21]Szwed M, Kania KD, Jozwiak Z. Assessment of pro-apoptotic activity of doxorubicin-transferrin conjugate in cells derived from human solid tumors. Int J Biochem Cell Biol. 2016;70: 57-67.

[22]Zhang R, Li J, Li J, et al. Efficient In vitro labeling rabbit bone marrow-derived mesenchymal stem cells with SPIO and differentiating into neural-like cells. Mol Cells. 2014;37(9):650-655.

[23] Gharib A, Faezizadeh Z, Mesbah-Namin SA, et al. Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. Daru. 2014;22:44.

[24]Hauser AK, Wydra RJ, Stocke NA, et al. Magnetic nanoparticles and nanocomposites for remote controlled therapies. J Control Release. 2015;219:76-94.

[25]Ferreira RV, Martins TM, Goes AM, et al. Thermosensitive gemcitabine-magnetoliposomes for combined hyperthermia and chemotherapy. Nanotechnology. 2016;27(8):085105.